2015 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle
10/07/15Novan Appoints Chief Financial Officer and Chief Commercial Officer to Leadership Team
Additions Strengthen Dermatology Capabilities as SB204 Advances toward Acne Market  DURHAM, N.C. (October 7, 2015) - Novan Therapeutics announced today the additions of two executives from the dermatology industry to the company’s leadership team.  Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer.  Mr. Peterson will be responsible for the company’s financial operations, investor relations, and other corporate function... 
09/29/15Novan Announces Successful Phase 2b Clinical Trial Results with SB204 for the Treatment of Acne Vulgaris
First-in-Class Nitric Oxide-Based Acne Therapy Set to Begin Phase 3 Trials in Early 2016 DURHAM, N.C. (September 29, 2015) - Novan Therapeutics announced today positive Phase 2b study results of its topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, achieving the company’s program goals.  The Phase 2b study demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and inflammatory (larger red bumps an... 
06/10/15Novan Adds Clinical Exposure and Safety Data to SB204 Acne Program
Results Presented at the 23rd World Congress of Dermatology; Company Anticipates Phase 2b Clinical Trial Results Third Quarter of 2015DURHAM, N.C. (June 10, 2015) - Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that following topical application of SB204 there was no measurable systemic exposure in patients with acne vulgaris.   SB204 was generally well-tolerated and not associated w... 
03/30/15Novan Secures $50 Million Private Financing
Funds Intended to Advance SB204 into Phase 3; Company Expands Board with the Addition of Three DirectorsDURHAM, N.C. (March 15, 2015) - Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing.  New investor Malin Corporation Plc. (ISEQ: MLC) functioned as the cornerstone investor along with strong participation from Novan’s exis... 
03/18/15Novan Achieves Target Enrollment for Phase 2 Acne Study
Company Positioned to Expand Clinical Dermatology Programs in 2015 DURHAM, N.C. (March 18, 2015) - Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that the Company has achieved target enrollment in its Phase 2b clinical study with SB204 for the treatment of acne vulgaris.  Acne is the most common skin disease in the United States, affecting more than 50 million people.  “The ... 
02/26/15Novan Expands Leadership Team with Vice President of Regulatory Affairs
Company Anticipates Start of Phase 3 Program for Lead Candidate, SB204, by Year-End 2015DURHAM, N.C. (February 26, 2015) - Novan Therapeutics, a clinical stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that Kevin Barber, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs, effective immediately. Dr. Barber will direct Novan’s regulatory strategy as the primary interface with the FDA... 
01/15/15Novan to Present Successful Clinical Study Results of Lead Product Candidate SB204 for the Treatment of Acne Vulgaris
Abstract Accepted for Presentation at the 23rd World Congress of Dermatology in June 2015DURHAM, N.C. (January 15, 2015) - Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that data from a clinical study to assess the safety and pharmacokinetics of SB204 Gel in patients with moderate to severe acne was accepted for presentation at the World Congress of Dermatology to be held in Vancouver on June 8-15, 2015.  This global event ...